When following a renal (kidney disease) diet, consuming foods low in sodium, phosphorus, potassium, and protein is crucial to ...

Its portfolio includes roxadustat, approved for treating anemia in chronic kidney disease patients across multiple regions, and FG-3246, an innovative antibody-drug conjugate targeting CD46 in ...

Yes, you can live with one kidney, whether you were born with one or later lost a kidney to disease or from being a donor.

Chronic kidney disease (CKD) affects millions worldwide, and as the demand for effective dialysis treatments grows, ...

The World Health Organization has defined chronic disease as non-communicable diseases enduring for long durations (five-year ...

On top of the substantial revenue generated by rosat and anemia associated with chronic kidney disease. If approved FiberGen will receive a $10 million milestone payment from our China partner ...

Purpose The evidence evaluating the efficacy of i.v. versus oral iron for the treatment of iron deficiency in non-hemodialysis-dependent patients with chronic kidney disease (CKD) is reviewed.

Disc Medicine (IRON) has obtained a $200 million non-dilutive term loan facility from Hercules Capital (HTGC). This financing provides funding ...

Facility significantly increases future financial and operational flexibilityUp to $200M available, with $30 million drawn at close and additional $80 million available at Disc’s sole discretion ...

In patients with cystic renal diseases (in whom mild or no anemia with elevated erythropoietin ... even in advanced chronic kidney disease; cysts derived from proximal tubules, but not those ...

Topline results from Phase 2 portion of the investigator-sponsored study of FG-3246, a first-in-class antibody-drug conjugate (ADC) targeting CD46, in combination with enzalutamide in patients with me ...

Disc Medicine, Inc. (NASDAQ:IRON) shares were firmly in the green Friday. The firm, a clinical-stage biopharmaceutical company focused on the discovery, development, and commercialization of novel ...